The role of CTGF in mediating the pathogenesis of diabetic nephropathy

Lead Research Organisation: Imperial College London
Department Name: Life Sciences

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
 
Title BIOLOGICAL MATERIALS AND USES THEREOF (1) 
Description The invention provides a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps: providing a CTGF receptor; providing a test sample; providing a CTGF receptor agonist; exposing the CTGF receptor to the test sample; subsequently or simultaneously exposing the CTGF receptor to the CTGF receptor agonist; detecting and/or measuring the amount of CTGF receptor activation; comparing the amount of CTGF receptor activation detected and/or measured in the presence of the test sample with the amount of CTGF receptor activation detected and/or measured in the absence of a test sample; determining if a compound reduces and/or prevents fibrosis on the basis that it causes no increase or a decrease in CTGF receptor activation. There is also provided compounds for reducing and/or preventing fibrosis and uses of such compounds. 
IP Reference WO2005050203 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact RMM and NW successfully applied for patents on anti-fibrotic therapeutic approaches based on (a) antagonising the interaction between CTGF and the receptor TrkA/p75NTR and (b) antagonising the CTGF-TIEG pathway triggered by CTGF-receptor ligation. There have been negotiations between Imperial Innovations Ltd (acting on behalf of the College) and the South San Francisco biotechnology company, FibroGen Inc., on their licensing of the above patents, but no agreement has been concluded as yet.
 
Title BIOLOGICAL MATERIALS AND USES THEREOF (2) 
Description The invention provides a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps: providing a cell type capable of expressing TIEG and/or Smad-7; providing a test compound; providing an amount of CTGF or a functional equivalent thereof, exposing the cell type to the test compound; subsequently or simultaneously exposing the cell type to the CTGF or functional equivalent thereof; detecting and/or measuring the expression of Smad-7 and TIEG; and comparing the amount of Smad-7 and/or TIEG expressed in the presence of the test compound with the amount of Smad-7 and/or TIEG produced detected and/or measured in the absence of a test compound; determining if a compound reduces and/or prevents fibrosis on the basis that it causes no change or an increase in Smad-7 expression and/or no change or a decrease in TIEG expression.; There is also provided compounds for reducing and/or preventing fibrosis and uses of such compounds. 
IP Reference WO2005050202 
Protection Patent application published
Year Protection Granted
Licensed Commercial In Confidence
Impact RMM and NW successfully applied for patents on anti-fibrotic therapeutic approaches based on (a) antagonising the interaction between CTGF and the receptor TrkA/p75NTR and (b) antagonising the CTGF-TIEG pathway triggered by CTGF-receptor ligation. There have been negotiations between Imperial Innovations Ltd (acting on behalf of the College) and the South San Francisco biotechnology company, FibroGen Inc., on their licensing of the above patents, but no agreement has been concluded as yet.